OTCMKTS:ACUR - Acura Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.28 0.00 (0.00 %)
(As of 07/23/2018 11:44 AM ET)
Previous Close$0.28
Today's Range$0.28 - $0.28
52-Week Range$0.2710 - $0.8702
Volume300 shs
Average Volume11,805 shs
Market Capitalization$5.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.5
Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.

Receive ACUR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolOTCMKTS:ACUR
CUSIP00509L70
Phone847-705-7709

Debt

Debt-to-Equity RatioN/A
Current Ratio0.24
Quick Ratio0.24

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.97 million
Price / Sales1.98
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-5,680,000.00
Net Margins-1,695.97%
Return on Equity-765.25%
Return on Assets-143.44%

Miscellaneous

Employees14
Outstanding Shares21,030,000
Market Cap$5.89

Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) posted its earnings results on Friday, June, 29th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter. The specialty pharmaceutical company had revenue of $0.20 million for the quarter. Acura Pharmaceuticals had a negative net margin of 1,695.97% and a negative return on equity of 765.25%. View Acura Pharmaceuticals' Earnings History.

What price target have analysts set for ACUR?

0 brokerages have issued 12 month price objectives for Acura Pharmaceuticals' shares. Their predictions range from $0.55 to $0.55. On average, they anticipate Acura Pharmaceuticals' stock price to reach $0.55 in the next twelve months. This suggests a possible upside of 96.4% from the stock's current price. View Analyst Ratings for Acura Pharmaceuticals.

What is the consensus analysts' recommendation for Acura Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acura Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Acura Pharmaceuticals' key competitors?

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert B. Jones, CEO, Pres & Director (Age 59)
  • Mr. Peter A. Clemens, Sr. VP, CFO & Sec. (Age 65)
  • Dr. Albert W. Brzeczko, VP of Technical Affairs (Age 61)
  • Mr. James F. Emigh, VP of Corp. Devel. (Age 62)
  • Mr. Robert A. Seiser Ph.D., VP, Treasurer & Corp. Controller (Age 54)

Has Acura Pharmaceuticals been receiving favorable news coverage?

Media coverage about ACUR stock has been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acura Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 45.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acura Pharmaceuticals' stock price today?

One share of ACUR stock can currently be purchased for approximately $0.28.

How big of a company is Acura Pharmaceuticals?

Acura Pharmaceuticals has a market capitalization of $5.89 million and generates $2.97 million in revenue each year. Acura Pharmaceuticals employs 14 workers across the globe.

How can I contact Acura Pharmaceuticals?

Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]


MarketBeat Community Rating for Acura Pharmaceuticals (OTCMKTS ACUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.